Yoo Hong Min

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1697555/publications.pdf

Version: 2024-02-01

		196777	242451
152	3,017	29	47
papers	citations	h-index	g-index
155	155	155	5347
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study. Cancer Research and Treatment, 2022, 54, 613-620.	1.3	2
2	Realâ€world data on prognostic value of measurable residual disease assessment by fragment analysis or nextâ€generation sequencing in multiple myeloma. British Journal of Haematology, 2022, , .	1.2	2
3	Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood, 2022, 140, 285-289.	0.6	15
4	Characteristics of community-acquired respiratory viruses infections except seasonal influenza in transplant recipients and non-transplant critically ill patients. Journal of Microbiology, Immunology and Infection, 2021, 54, 253-260.	1.5	16
5	Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma. Clinical Cancer Research, 2021, 27, 2947-2958.	3.2	24
6	Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma. Korean Journal of Internal Medicine, 2021, 36, S245-S252.	0.7	0
7	Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells. Experimental Hematology and Oncology, 2021, 10, 28.	2.0	12
8	Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry. PLoS ONE, 2021, 16, e0251011.	1.1	4
9	Detection of recurrent, rare, and novel gene fusions in patients with acute leukemia using nextâ€generation sequencing approaches. Hematological Oncology, 2020, 38, 82-88.	0.8	15
10	Immunosuppressive role of CD11b ⁺ CD33 ⁺ HLAâ€DR ^{â^²} myeloidâ€derived suppressor cellsâ€like blast subpopulation in acute myeloid leukemia. Cancer Medicine, 2020, 9, 7007-7017.	1.3	12
11	RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. Scientific Reports, 2020, 10, 20119.	1.6	6
12	Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma. Annals of Hematology, 2020, 99, 2149-2157.	0.8	4
13	ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia. Journal of Experimental and Clinical Cancer Research, 2020, 39, 85.	3.5	23
14	PERK/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells. Journal of Experimental and Clinical Cancer Research, 2020, 39, 66.	3.5	39
15	Serum albumin and C-reactive protein as significant predictors of non-relapse mortality in lower gastrointestinal graft-versus-host disease. Annals of Hematology, 2020, 99, 1111-1119.	0.8	3
16	All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells. Yonsei Medical Journal, 2020, 61, 762.	0.9	6
17	Induction of apoptosis and differentiation by Na/H exchanger 1 modulation in acute myeloid leukemia cells. Biochemical and Biophysical Research Communications, 2019, 519, 887-893.	1.0	8
18	Early Cytomegalovirus Reactivation and Expansion of CD56brightCD16dim/â^'DNAM1+ Natural Killer Cells Are Associated with Antileukemia Effect after Haploidentical Stem Cell Transplantation in Acute Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 2070-2078.	2.0	16

#	Article	IF	CITATIONS
19	Targeted next generation sequencing can serve as an alternative to conventional tests in myeloid neoplasms. PLoS ONE, 2019, 14, e0212228.	1.1	11
20	Different prognostic effects of core-binding factor positive AML with Korean AML registry data. Annals of Hematology, 2019, 98, 1135-1147.	0.8	9
21	<i>FLT3 </i> lnternal Tandem Duplication in Patients With Acute Myeloid Leukemia Is Readily Detectable in a Single Next-Generation Sequencing Assay Using the Pindel Algorithm. Annals of Laboratory Medicine, 2019, 39, 327-329.	1.2	10
22	YAP and TAZ in Fibroblastic Reticular Cells Support Hematopoiesis and Retention of Lymphocytes in Lymph Nodes. Blood, 2019, 134, 3595-3595.	0.6	2
23	Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment NaÃve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles. Blood, 2019, 134, 2591-2591.	0.6	12
24	Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na \tilde{A} -ve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study. Blood, 2019, 134, 4235-4235.	0.6	1
25	HBsAg-Negative, Anti-HBc–Negative Patients Still Have a Risk of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma. Cancer Research and Treatment, 2018, 50, 1121-1129.	1.3	4
26	Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience. Annals of Hematology, 2017, 96, 605-615.	0.8	5
27	Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells. Autophagy, 2017, 13, 761-762.	4.3	60
28	The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma. Annals of Hematology, 2017, 96, 1163-1173.	0.8	12
29	Prognostic significance of interventricular septal thickness in patients with AL amyloidosis. Leukemia Research, 2017, 60, 36-43.	0.4	3
30	AMPK–ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells. Clinical Cancer Research, 2017, 23, 2781-2794.	3.2	104
31	Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large Bâ€cell lymphoma. Hematological Oncology, 2017, 35, 465-471.	0.8	5
32	Clinical characteristics and treatment outcomes of isolated myeloid sarcoma without bone marrow involvement: a single-institution experience. Blood Research, 2017, 52, 184.	0.5	18
33	Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia. Yonsei Medical Journal, 2017, 58, 35.	0.9	15
34	Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma. Oncotarget, 2017, 8, 87317-87328.	0.8	30
35	Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. Oncotarget, 2017, 8, 92312-92323.	0.8	11
36	Factors associated with pulmonary toxicity after myeloablative conditioning using fractionated total body irradiation. Radiation Oncology Journal, 2017, 35, 257-267.	0.7	6

#	Article	IF	CITATIONS
37	Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens. Journal of Korean Medical Science, 2016, 31, 510.	1.1	11
38	Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. PLoS ONE, 2016, 11, e0166245.	1.1	6
39	The role of upfront autologous stem cell transplantation in highâ€risk younger patients with primary central nervous system lymphoma. British Journal of Haematology, 2016, 174, 444-453.	1.2	10
40	Cytogenetic profiles of 2806 patients with acute myeloid leukemiaâ€"a retrospective multicenter nationwide study. Annals of Hematology, 2016, 95, 1223-1232.	0.8	14
41	Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance. Molecular Medicine Reports, 2016, 13, 3433-3440.	1.1	19
42	The prognostic significance of monoclonal immunoglobulin gene rearrangement in conjunction with histologic Bâ€cell aggregates in the bone marrow of patients with diffuse large Bâ€cell lymphoma. Cancer Medicine, 2016, 5, 1066-1073.	1.3	7
43	The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. Annals of Hematology, 2016, 95, 1491-1501.	0.8	9
44	A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. European Journal of Cancer, 2016, 57, 127-135.	1.3	28
45	High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. Leukemia and Lymphoma, 2016, 57, 51-57.	0.6	15
46	The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications. Tumor Biology, 2016, 37, 2037-2047.	0.8	18
47	NOTCH2 missplicing can occur in relation to apoptosis. Blood, 2015, 126, 1731-1732.	0.6	2
48	Red nail folds and Gottron's sign in a patient with leukemic infiltration of pelvic muscles. JDDG - Journal of the German Society of Dermatology, 2015, 13, 581-582.	0.4	0
49	Rote Nagelfalze und Gottron-Zeichen bei einem Patienten mit leukÄmischer Infiltration der Beckenmuskulatur. JDDG - Journal of the German Society of Dermatology, 2015, 13, 581-583.	0.4	0
50	Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine. Biomedicine and Pharmacotherapy, 2015, 73, 87-96.	2.5	29
51	Tear Cytokines as Biomarkers for Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 2079-2085.	2.0	61
52	Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome. Acta Haematologica, 2015, 134, 40-48.	0.7	12
53	Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Annals of Hematology, 2015, 94, 275-282.	0.8	45
54	The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen. Yonsei Medical Journal, 2014, 55, 1568.	0.9	21

#	Article	IF	CITATIONS
55	Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes. PLoS ONE, 2014, 9, e86933.	1.1	26
56	Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea. Journal of Korean Medical Science, 2014, 29, 61.	1.1	4
57	Clinical Outcomes and Prognostic Factors of Empirical Antifungal Therapy with Itraconazole in the Patients with Hematological Malignancies: A Prospective Multicenter Observational Study in Korea. Yonsei Medical Journal, 2014, 55, 9.	0.9	1
58	Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. Transfusion, 2014, 54, 1542-1551.	0.8	45
59	Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response. Annals of Hematology, 2014, 93, 211-219.	0.8	10
60	The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea. Annals of Hematology, 2014, 93, 33-42.	0.8	8
61	Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scandinavian Journal of Infectious Diseases, 2014, 46, 81-88.	1.5	33
62	Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. Annals of Hematology, 2014, 93, 1867-1877.	0.8	16
63	Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients. International Journal of Hematology, 2014, 100, 141-151.	0.7	5
64	High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 73-79.	2.0	17
65	Inhibition of NHE1 Induced Apoptosis in Cytarabine Resistant Leukemia Cell Lines and Primary Leukemia Cells from AML Patients, Which Showed Increased Intracellular pH and NHE1 Activity. Blood, 2014, 124, 3614-3614.	0.6	1
66	Autophagy Inhibition Overcomes Resistance to Cytosine Arabinoside in Acute Myeloid Leukemia Cells through Inducing Autophagic Cell Death and Intrinsic Pathway Apoptosis. Blood, 2014, 124, 909-909.	0.6	1
67	Clinical Limitations of Surveillance Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography According to Histologic Subtypes in Patients with Malignant Lymphoma Who Achieved Complete Remission. Blood, 2014, 124, 1736-1736.	0.6	0
68	The New Prognostic Model Using Whole Blood Epstein-Barr Virus-DNA Positivity and Low Absolute Lymphocyte Count in Patients with Primary Central Nerve System Lymphoma. Blood, 2014, 124, 3014-3014.	0.6	0
69	Salvage Chemotherapy Followed By Autologous Peripheral Stem Cell Transplantation for Relapsed Acute Promyelocytic Leukemia; A Single Center Experience. Blood, 2014, 124, 4000-4000.	0.6	0
70	Improved Sensitivity and Discriminative Power of Factor FVIII Assay By Applying Turbidimetric Clotting Curve Analysis. Blood, 2014, 124, 2853-2853.	0.6	0
71	Post-Autotransplant Hepatitis B Virus (HBV) Reactivation in Lymphoma and Multiple Myeloma Patients with Hepatitis B Surface Antigen-Positive or Resolved HBV Infection. Blood, 2014, 124, 1196-1196.	0.6	0
72	Delta-Neutrophil Index Is a Useful Indicator for Initiation of Peripheral Blood Stem Cell Collection in Chemo-Mobilized Patients. Blood, 2014, 124, 2457-2457.	0.6	1

#	Article	IF	CITATIONS
73	Upfront Autologous Stem Cell Transplantation Overcome the poor Prognosis of Non-Germinal Center Subtype of diffuse Large B-Cell Lymphoma in Patients with Advanced Stage and Elevated Serum Lactate Dehydrogenase. Blood, 2014, 124, 3998-3998.	0.6	0
74	Prognostic Factors in Adult Patients with Acute Promyelocytic Leukemia Receiving ATRA-Based Treatment. Blood, 2014, 124, 5274-5274.	0.6	0
75	Fludarabine, cytarabine, and attenuatedâ€dose idarubicin (mâ€FLAI) combination therapy for elderly acute myeloid leukemia patients. American Journal of Hematology, 2013, 88, 10-15.	2.0	14
76	Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. British Journal of Haematology, 2013, 161, 339-347.	1.2	72
77	Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells. Oncology Letters, 2013, 5, 588-592.	0.8	15
78	Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry. Blood Research, 2013, 48, 115.	0.5	5
79	Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients. Blood Research, 2013, 48, 24.	0.5	10
80	Risk Factors For The Development Of Severe Bacterial Infection In Patients With Multiple Myeloma During Chemotherapy With Bortezomib Containing Regimens. Blood, 2013, 122, 5370-5370.	0.6	1
81	Carbonyl Reductase 1 Offers a Novel Therapeutic Target to Enhance Leukemia Treatment by Arsenic Trioxide. Cancer Research, 2012, 72, 4214-4224.	0.4	24
82	Risk Factors for Progression from Cytomegalovirus Viremia to Cytomegalovirus Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 881-886.	2.0	28
83	Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). Journal of Hematology and Oncology, 2012, 5, 49.	6.9	83
84	Anaphylactic Transfusion Reaction in a Patient with Anhaptoglobinemia: The First Case in Korea. Annals of Laboratory Medicine, 2012, 32, 304-306.	1.2	10
85	Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells. The Korean Journal of Hematology, 2012, 47, 178.	0.7	14
86	Myeloperoxidase Expression in Acute Myeloid Leukemia Helps Identifying Patients to Benefit from Transplant. Yonsei Medical Journal, 2012, 53, 530.	0.9	19
87	Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Medical Oncology, 2012, 29, 1179-1185.	1.2	38
88	Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leukemia and Lymphoma, 2011, 52, 1024-1029.	0.6	29
89	Clinical significance of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. The Korean Journal of Hematology, 2011, 46, 175.	0.7	7
90	Resveratrol Alters microRNA Expression Profiles in A549 Human Non-Small Cell Lung Cancer Cells. Molecules and Cells, 2011, 32, 243-250.	1.0	86

#	Article	IF	CITATIONS
91	Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. Journal of Hematology and Oncology, 2011, 4, 34.	6.9	37
92	Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. Annals of Hematology, 2010, 89, 15-23.	0.8	10
93	Prognostic significance of trisomy 6 in an adult acute myeloid leukemia with t(8;21). Cancer Genetics and Cytogenetics, 2010, 202, 141-143.	1.0	3
94	Primary renal aspergillosis and renal stones in both kidneys associated with hematopoietic stem cell transplant. The Korean Journal of Hematology, 2010, 45, 275.	0.7	3
95	Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica, 2010, 95, 1935-1942.	1.7	95
96	Re-analysis of the Outcomes of Post-Remission Therapy for Acute Myeloid Leukemia with Core Binding Factor According to Years of Patient Enrolment. Japanese Journal of Clinical Oncology, 2010, 40, 556-566.	0.6	10
97	Myeloperoxidase Expression as a Potential Determinant of Parthenolide-Induced Apoptosis in Leukemia Bulk and Leukemia Stem Cells. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 389-400.	1.3	34
98	Cytogenetic features of 5q deletion and 5qâ^' syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization. Cancer Genetics and Cytogenetics, 2010, 203, 193-202.	1.0	5
99	Aurora-A kinase inhibition enhances the cytosine arabinoside-induced cell death in leukemia cells through apoptosis and mitotic catastrophe. Cancer Letters, 2010, 297, 171-181.	3.2	15
100	A Successful Treatment of Relapsed Primary CNS Lymphoma Patient with Intraventricular Rituximab Followed by High-Dose Chemotherapy with Autologous Stem Cell Rescue. Yonsei Medical Journal, 2009, 50, 280.	0.9	13
101	Three-way Philadelphia variant $t(9;22;14)(q34;q11.2;p11)$ in chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 2009, 191, 55-56.	1.0	1
102	Association between acute promyelocytic leukemia and ring chromosome 6. Cancer Genetics and Cytogenetics, 2009, 192, 48-50.	1.0	3
103	Detection of FUS–ERG chimeric transcript in two cases of acute myeloid leukemia with t(16;21)(p11.2;q22) with unusual characteristics. Cancer Genetics and Cytogenetics, 2009, 194, 111-118.	1.0	17
104	Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 463-470.	2.0	55
105	Functional Recovery after the Transplantation of Neurally Differentiated Mesenchymal Stem Cells Derived from Bone Barrow in a Rat Model of Spinal Cord Injury. Cell Transplantation, 2009, 18, 1359-1368.	1.2	79
106	Treatment Outcome of Steroid-Refractory Chronic Graft-Versus-Host Disease with Weekly Rituximab Followed by Maintenance Rituximab: a KSBMT Multicenter Phase II Study Blood, 2009, 114, 1151-1151.	0.6	0
107	Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea Blood, 2009, 114, 4298-4298.	0.6	0
108	Paracentric inversion–associated t(8;21) variant in de novo acute myelogenous leukemia: characteristic patterns of conventional cytogenetics, FISH, and multicolor banding analysis. Cancer Genetics and Cytogenetics, 2008, 183, 72-76.	1.0	4

#	Article	IF	CITATIONS
109	Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation $t(3;21)(q26;q22)$ and RUNX1â \in "MDS1â \in "EVI1 fusion transcript. Cancer Genetics and Cytogenetics, 2008, 187, 61-73.	1.0	24
110	Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation with Alemtuzumab. Ophthalmology, 2008, 115, 1766-1770.	2.5	40
111	Transfusion-Associated Iron Overload as an Adverse Risk Factor for Transplantation Outcome in Patients Undergoing Reduced-Intensity Stem Cell Transplantation for Myeloid Malignancies. Acta Haematologica, 2008, 120, 182-189.	0.7	33
112	Prognostic implications of the immunophenotype in biphenotypic acute leukemia. Leukemia and Lymphoma, 2008, 49, 700-709.	0.6	44
113	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide,) Tj ETQq1 1 0.7843 Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial Blood. 2008, 112, 3330-3330.	314 rgBT / 0.6	Overlock 10 22
114	A Case Report of Posttransplant Lymphoproliferative Disorders Successfully Treated with R-CHOP in Korea. The Korean Journal of Hematology, 2008, 43, 106.	0.7	1
115	Statistical Correlations Between Quantifiable Disease Variables and Prognosis in Hematological Malignancy Patients Treated with Itraconazole as An Empirical Antifungal Therapy: A Prospective Multicenter Observational Study in Korea. Blood, 2008, 112, 4028-4028.	0.6	16
116	Protein Kinase CK2 $\hat{1}$ ± as an Unfavorable Prognostic Marker and Novel Therapeutic Target in Acute Myeloid Leukemia. Clinical Cancer Research, 2007, 13, 1019-1028.	3.2	184
117	Long-term Follow-up of Laparoscopic Splenectomy in Patients with Immune Thrombocytopenic Purpura. Journal of Korean Medical Science, 2007, 22, 420.	1.1	19
118	The Clinical Guidelines for Myelodysplastic Syndrome. The Korean Journal of Hematology, 2007, 42, 71.	0.7	1
119	Long-term Outcome after Prophylactic Lamivudine Treatment on Hepatitis B Virus Reactivation in Non-Hodgkin's Lymphoma. Yonsei Medical Journal, 2007, 48, 78.	0.9	17
120	t(5;12)(q13;p13) in acute myeloid leukemia with preceding granulocytic sarcoma. Cancer Genetics and Cytogenetics, 2007, 177, 158-160.	1.0	4
121	Allogeneic Stem Cell Transplantation Can Be an Effective Post-Remission Strategy for Acute Myeloid Leukemia Patients Aged Less Than 60 Years with Core Binding Factor: A Nation-Wide Retrospective Study in Korea Blood, 2007, 110, 1092-1092.	0.6	29
122	Myelodysplastic Syndrome. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2006, 49, 897.	0.1	1
123	A Report of AIDS-Related Lymphoma (ARL) in Korea Blood, 2006, 108, 4687-4687.	0.6	O
124	A Case of Serum Amino Acid Disturbance with Hyperammonemia in Patient with Primary Amyloidosis. The Korean Journal of Hematology, 2005, 40, 54.	0.7	0
125	Two Cases of Acquired Hemophilia A Successfully Treated with Oral Steroid or Danazol. The Korean Journal of Hematology, 2005, 40, 58.	0.7	1
126	Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biology of Blood and Marrow Transplantation, 2005, 11, 122-128.	2.0	35

#	Article	IF	CITATIONS
127	Recurrent Secondary Pneumothorax Caused by Bronchiolitis Obliterans Due to Chronic Graft Versus Host Disease in a Patient with Chronic Myelogenous Leukemia after Allogenic Bone Marrow Transplantation. Tuberculosis and Respiratory Diseases, 2004, 57, 183.	0.7	1
128	Cytoplasmic Mislocalization of p27Kip1 Protein Is Associated with Constitutive Phosphorylation of Akt or Protein Kinase B and Poor Prognosis in Acute Myelogenous Leukemia. Cancer Research, 2004, 64, 5225-5231.	0.4	88
129	Elevated S-Phase Kinase-Associated Protein 2 Protein Expression in Acute Myelogenous Leukemia. Clinical Cancer Research, 2004, 10, 5123-5130.	3.2	35
130	Chronic Graft-versus-Host Disease of the Liver Presenting as an Acute Hepatitis following Nonmyeloablative Hematopoietic Stem Cell Transplantation. International Journal of Hematology, 2004, 79, 501-504.	0.7	13
131	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. British Journal of Haematology, 2004, 124, 166-178.	1.2	37
132	Ex Vivo Expansion of Human Umbilical Cord Blood CD34+ Cells in a Collagen Beadâ€"Containing 3-Dimensional Culture System. International Journal of Hematology, 2003, 78, 126-132.	0.7	30
133	Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. British Journal of Haematology, 2003, 122, 454-456.	1.2	77
134	Constitutive phosphorylation of FKHR transcription factor as a prognostic variable in acute myeloid leukemia. Leukemia Research, 2003, 27, 1159-1162.	0.4	35
135	Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells. Clinical Cancer Research, 2003, 9, 5018-27.	3.2	57
136	Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched hu. British Journal of Haematology, 2002, 118, 1128-1131.	1.2	129
137	Long-term bone marrow culture-derived stromal fibroblasts as a potential target for gene therapy in acute myelogenous leukemia. Leukemia Research, 2002, 26, 369-376.	0.4	6
138	Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia. Yonsei Medical Journal, 2001, 42, 65.	0.9	1
139	Non-Hodgkin's Lymphoma & Primary Biliary Cirrhosis with Sjögren's Syndrome. Yonsei Medical Journal, 2001, 42, 258.	0.9	8
140	Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. American Journal of Hematology, 2001, 68, 237-245.	2.0	21
141	AC133 antigen as a prognostic factor in acute leukemia. Leukemia Research, 2001, 25, 757-767.	0.4	14
142	Surface expression of HLA-DM on dendritic cells derived from CD34-positive bone marrow haematopoietic stem cells. British Journal of Haematology, 2000, 110, 385-393.	1.2	10
143	Laparoscopic splenectomy for immune thrombocytopenic purpura:long-term result of 40 laparoscopic splenectomies. Yonsei Medical Journal, 1999, 40, 578.	0.9	17
144	Ex vivogeneration of functional dendritic cells from mobilized CD34+hematopoietic stem cells. Yonsei Medical Journal, 1998, 39, 328.	0.9	8

#	Article	IF	CITATIONS
145	Eight-year experience of malignant lymphoma: survival and prognostic factors. Yonsei Medical Journal, 1997, 38, 270.	0.9	13
146	Monitoring of WT-1 gene expression in peripheral blood of patients with acute leukemia by semiquantitative RT-PCR; possible marker for detection of minimal residual leukemia. Yonsei Medical Journal, 1997, 38, 212.	0.9	7
147	Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy. British Journal of Haematology, 1996, 93, 928-930.	1.2	69
148	CD34 immunohistochemical staining of bone marrow biopsies in myelodysplastic syndromes. Yonsei Medical Journal, 1995, 36, 1.	0.9	1
149	Differential responses of CD34-positive acute myelogenous leukemic blasts to the costimulating effects of stem cell factor with GM-CSF and/or IL-3. Yonsei Medical Journal, 1995, 36, 26.	0.9	0
150	Primary lymphoma of the thyroid. Yonsei Medical Journal, 1995, 36, 315.	0.9	6
151	GM-CSF and low-dose araC treatment of AML in prolonged hypoplasia with residual leukemic cells after induction chemotherapy. Yonsei Medical Journal, 1994, 35, 91.	0.9	1
152	Liver Involvement in Multiple Myeloma Proven by Peritoneoscopy. Yonsei Medical Journal, 1993, 34, 90.	0.9	8